A Greek SME with significant research and professional experience in the field of biomedical engineering and mainly in the emerging molecular imaging technology has developed two novel systems for in-vivo molecular imaging.
Molecular imaging is now a standard, efficient tool in clinical and mainly preclinical research for the study of new drugs, biomolecules and nanoparticles. Based on that, the Greek company is focused in the use of radioisotopes to label and image those molecules. Although multimodal imaging systems exist, their purchase and maintenance cost is non affordable to the majority of small and medium research groups. To this direction, they are developing low cost, benchtop imaging systems, which can be easily acquired by any research team working in the field of biotechnology and medical research worldwide.
Currently, two systems are provided which cover the complementary techniques of SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) isotopes. Both systems are benchtop and can fill in the gap between ex-vivo biodistributions and advanced imaging systems. They have a 5x10 cm² field of view, allowing whole-body mice studies and they support static and fast dynamic whole-body imaging. Their size is comparable to a small printer and they can transform a lab desk into an in vivo imaging laboratory. Their small size and weight allow easy transport to other labs for providing imaging services.
Furthermore, the systems operate in planar mode, the most efficient method for fast, in vivo screening. They are also provided with laptop and preinstalled software for data acquisition, archiving, imaging and data analysis, as well as a durable packing suitcase and all components ready for immediate use.
In addition, they can be used as stand-alone imaging systems for whole-body dynamic studies, as well as fast screening of biomolecules before detailed studies. Also, they are the only systems that provide real-time images when the animal is placed on the camera bed and they can be used to detect rather low activities and concentrations.
Moreover, the proposed systems can be used for quality control in imaging before ex vivo biodistributions and pre-screening before multimodal imaging. Finally, they can significantly improve accuracy and statistics and they are in compliance with bioethics and request for animals’ reduction.
Based on all the above, the proposed systems constitute cost effective solutions in terms of instrumentation and services for in-vivo imaging of radiolabeled biomolecules and nanoparticles.
The Greek company is in need of finding partners from both academic and private sectors willing to adopt, deliver or further develop the proposed systems and also provide feedback for optimization for new applications under the context of commercial agreement with technical assistance. Also, private partners are sought to further develop hardware, marketing and international presence. The desired type of cooperation is joint venture agreement.